Brief: Poseida Therapeutics Highlights Recent Progress, Strategic Priorities And Anticipated 2024 Key Milestones

Poseida Therapeutics

04/01/2024 13:52

Jan 4 (Reuters) - Poseida Therapeutics Inc  PSTX.O :
    * POSEIDA THERAPEUTICS HIGHLIGHTS RECENT PROGRESS, STRATEGIC
PRIORITIES AND ANTICIPATED 2024 KEY MILESTONES
    * PLAN TO REPORT CLINICAL DATA UPDATES FOR P-BCMA-ALLO1AND
P-MUC1C-ALLO1 ALLOGENEIC CAR-T PROGRAMS AT SCIENTIFIC MEETINGS
IN 2024
    * EXPECT TO DOSE FIRST PATIENT IN PHASE 1 P-CD19CD20-ALLO1
TRIAL
IN EARLY 2024
    * IN 2024, POSEIDA PLANS TO CONTINUE DEVELOPMENT OF
P-BCMA-ALLO1
IN PARTNERSHIP WITH ROCHE
    * PLANS TO PRESENT ADDITIONAL CLINICAL DATA UPDATES FOR
P-BCMA-ALLO1 AT MEETINGS IN 2024, SUBJECT TO COORDINATION WITH
ROCHE

Source text for Eikon:  ID:nPn5Wjq3Ka 
Further company coverage:  PSTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))